Accession Number: | 0001209191-20-045105 |
Date: | 2020-08-03 |
Issuer: | VERTEX PHARMACEUTICALS INC / MA (VRTX) |
Original Submission Date: |
SILVA PAUL M
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON, MA 02210
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2020-08-03 | M | 809 | a | $86.52 | 15,741 | direct | ||
COMMON STOCK | 2020-08-03 | S | 51 | d | $276.00 | 15,690 | direct | ||
COMMON STOCK | 2020-08-03 | S | 310 | d | $277.73 | 15,380 | direct | ||
COMMON STOCK | 2020-08-03 | S | 429 | d | $278.92 | 14,951 | direct | ||
COMMON STOCK | 2020-08-03 | S | 19 | d | $279.61 | 14,932 | direct | ||
COMMON STOCK | 2020-08-03 | 0 | $0.00 | 169 | indirect |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
STOCK OPTION (RIGHT TO BUY) | 86.52 | 2020-08-03 | deemed execution date | M | 809 (d) | 2027-02-02 | common stock 809 | $86.52 | 1,618 | direct |
ID | footnote |
---|---|
f1 | transaction made pursuant to mr. silva's company approved trading plan under rule 10b5-1. |
f2 | open market sales reported on this line occurred at a weighted average price of $277.73 (range $277.25 to $278.22). |
f3 | mr. silva undertakes to provide (upon request by the sec staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
f4 | open market sales reported on this line occurred at a weighted average price of $278.92 (range $278.47 to $279.38). |
f5 | the option vests in 16 quarterly installments from 02/03/2017. |